2024
HIV Activist Identity, Commitment, and Orientation Scale (HAICOS): Psychometric Evaluation to Assess Clinician’s Propensity Towards HIV Activism in Malaysia
Chong N, Azwa I, Hassan A, Mousavi M, Wong P, Ng R, Saifi R, Basri S, Omar S, Walters S, Collier Z, Haddad M, Altice F, Kamarulzaman A, Earnshaw V. HIV Activist Identity, Commitment, and Orientation Scale (HAICOS): Psychometric Evaluation to Assess Clinician’s Propensity Towards HIV Activism in Malaysia. AIDS And Behavior 2024, 28: 2780-2792. PMID: 38806844, DOI: 10.1007/s10461-024-04381-4.Peer-Reviewed Original ResearchConceptsExploratory factor analysisHIV-related stigmaIntra-class correlation coefficientPrimary care physiciansTest-retest reliabilityCronbach's alpha valuesOrientation ScaleCare physiciansStigma-relatedPsychometric evaluationHIV treatmentHIV activityAlpha valuesPsychometric qualitiesActivist identitiesHIVClinical practiceFactor analysisCliniciansCorrelation coefficientDay-to-dayStructured activitiesCronbachStigmaPhysicians
2020
Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine
Meteliuk A, Galvez de Leon SJ, Madden LM, Pykalo I, Fomenko T, Filippovych M, Farnum SO, Dvoryak S, Islam ZM, Altice FL. Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine. Journal Of Substance Use And Addiction Treatment 2020, 121: 108164. PMID: 33191004, PMCID: PMC7769928, DOI: 10.1016/j.jsat.2020.108164.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyTake-home dosingInterim guidanceShort-term overall mortalityOpioid agonist treatment programPerson clinical encountersOAT deliveryAgonist therapyOverall mortalityCOVID-19 transmissionPatient dropoutOAT patientsNaloxone distributionOverdose educationClinical practiceClinic interactionsTreatment programClinical encountersPatientsCliniciansCOVID-19COVID-19 pandemicOverdosesDosingPrevious year
2015
Validation of the ‘drinking expectancy questionnaire for men who have sex with men’ in Peru
Vagenas P, Wickersham JA, Calabrese SK, Lama JR, Benites CM, Pun M, Sanchez J, Altice FL. Validation of the ‘drinking expectancy questionnaire for men who have sex with men’ in Peru. Drug And Alcohol Review 2015, 34: 559-566. PMID: 26120824, PMCID: PMC4795987, DOI: 10.1111/dar.12282.Peer-Reviewed Original ResearchTransgender womenRisky sexual behaviorIntervention targetsHigh-risk MSMSexual behaviorAlcohol use disorderHigh-risk behaviorsSpanish versionPotential intervention targetsPeruvian MSMHIV epidemicGeneral populationUse disordersClinical practiceMSMShort instrumentTwo-factor structureFurther screeningProblematic drinkingExpectancyMenExploratory factor analysisExpectancy QuestionnairePopulationLarge population
2013
A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice
Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Review Of Clinical Pharmacology 2013, 6: 249-269. PMID: 23656339, PMCID: PMC4198941, DOI: 10.1586/ecp.13.18.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyAntiretroviral therapyDrug interactionsAgonist therapyHIV medicationsHepatitis C virus medicationsHepatitis C virus (HCV) treatmentActive antiretroviral therapyC virus treatmentPharmacodynamic drug interactionsImportant clinical consequencesReview of abstractsHCV therapyAntiretroviral agentsPharmacodynamic interactionsPharmacological interactionsHIV therapyClinical consequencesVirus treatmentClinical practiceFollowing keywordsTherapyClinical implicationsMedicationsMethadone
2008
Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice
Bruce RD, Altice FL, Friedland GH. Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice. Expert Review Of Clinical Pharmacology 2008, 1: 115-127. PMID: 24410515, DOI: 10.1586/17512433.1.1.115.Peer-Reviewed Original ResearchPharmacokinetic drug interactionsDrugs of abuseDrug interactionsAntiretroviral therapyHIV treatmentActive illicit drug useClinical implicationsImportant pharmacokinetic drug interactionsClinical case seriesImportant clinical consequencesIllicit drug useHIV/AIDSMetabolism of drugsPharmacokinetic interaction studyAntiretroviral medicationsCase seriesTreatable diseaseClinical consequencesClinical practiceDrug useMedical consequencesSubstance abuseTherapyDrugsAbuse